[Direct Report Network Beijing January 28th] (Economic Reference Network) Kangmei Pharmaceutical, which has been in the center of public opinion storms, recently held the "Kangmei Pharmaceutical 2018 Work Summary and Commendation Conference" at its Puning Headquarters in Guangdong. Ma Xingtian, chairman and president of Kangmei Pharmaceutical, proposed that Kangmei Pharmaceutical will focus on its main business, slim down and continue to adhere to the development path of Chinese medicine industry.

 

It is understood that in recent years, Kangmei Pharmaceutical's net profit has maintained rapid growth, and its net profit has increased by more than 20% for many consecutive years. According to the third quarterly report of Kangmei Pharmaceutical in 2018, as of the end of the third quarter of 2018, the company's total operating income was 25.428 billion yuan, a year-on-year increase of 30.31%, which was close to the 2017 annual figure of 26.477 billion yuan; net profit was 3.847 billion yuan, an increase of 22.10%.

 

Ma Xingtian said that in the new year, Kangmei Pharmaceutical will adhere to the development of industry, focus on the main business, slimming up and strengthening the foundation. It is necessary to take Chinese herbal medicines as the core and use smart pharmacies as the starting point to promote supply chain extension services and drive the growth of pharmaceutical trade business. The Smart Pharmacy accelerates the nationwide structural coverage and ensures that the daily prescription volume is 250,000 in three years; and it combines the “Smart+” big health platform, hospital sales, OTC, retail, chain pharmacies, e-commerce, etc. to achieve three-dimensional and service-oriented Channel marketing network, vigorously develop and establish a C-end market brand; accelerate the integration of medical device channels and resources, increase the control of upstream high-quality resources, and comprehensively build a high-quality medical device service platform.

 

In order to achieve this goal, Ma Xingtian proposed "five enhancements" - the first is to strengthen the use of traditional Chinese medicine decoction pieces as the core, with the wisdom pharmacy as the starting point, to comprehensively enhance the market share of traditional Chinese medicine decoction pieces; the second is to strengthen the wisdom pharmacy, wisdom medicine cabinet and medicine hoist The “Trinity” of the big health platform to achieve a highly viscous C-end business model; the third is to strengthen the integration of medical device channels and resources, to create a medical device commercial platform and achieve new breakthroughs in profits; the fourth is to strengthen the profit model of the medical system, in hospital management, The medical service platform system has achieved new breakthroughs in revenue; the fifth is to strengthen the company's organizational structure, management, talent system, corporate culture, and build up the internal driving force to achieve the continued sublimation of the Kangmei brand.

 

At this meeting, Kangmei Pharmaceutical also proposed the company's strategic goal for the next three years: focus on the company's core business and enhance the company's core competitiveness. Taking Chinese Herbal Medicine as the core, using smart pharmacy and smart medicine cabinet as the starting point, and taking “medicine hoist” as the service platform, it will form a highly viscous C-end business model, and realize the health of traditional Chinese medicine manufacturing enterprises to * service-oriented Chinese medicine. Business Transformation.

 

Ma Xingtian also stressed that Kangmei Pharmaceutical will further promote online centralized procurement to achieve cost reduction and efficiency. Improve the function of online procurement platform, continue to promote the digital procurement process, complete the procurement management system, achieve the strategic goal of comprehensive online centralized procurement, ensure the timely supply of products, reduce the overall procurement cost of traditional Chinese medicine decoction pieces, and further enhance business benefits. "In 2019, the overall business cost was reduced by 10%." Ma Xingtian said.